Exploratory study of the dose-related safety, tolerability, and efficacy of dimethyltryptamine (DMT) in healthy volunteers and major depressive disorder

In this small exploratory pilot study, intravenous DMT at doses of 0.1 and 0.3 mg/kg was mostly safe and tolerated and may have next-day antidepressant effects in patients with treatment-resistant MDD and further rigorous trials are warranted to replicate these findings and to determine the durability of antidepressant effects.